Positron emission tomography and improved survival in patients with lung cancer - The Will Rogers phenomenon revisited

被引:70
作者
Chee, Karen G. [1 ]
Nguyen, Danh V. [2 ,5 ]
Brown, Monica [4 ]
Gandara, David R. [1 ,3 ]
Wun, Ted [1 ,2 ,3 ]
Lara, Primo N., Jr. [1 ,3 ]
机构
[1] UC Davis Hlth System, UC Davis Canc Ctr, Sacramento, CA 95817 USA
[2] UC Davis Hlth System, UC Davis Clin & Translat Sci Ctr, Sacramento, CA 95817 USA
[3] Vet Adm No Calif Hlth Care System, Sacramento, CA USA
[4] Calif Canc Registry, Canc Surveillance Program, Sacramento, CA USA
[5] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA
关键词
D O I
10.1001/archinte.168.14.1541
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Will Rogers phenomenon occurs when newer technology allows for more sensitive detection of tumor spread, resulting in stage migration and an apparent improvement in patient survival. We investigated whether use of highly sensitive positron emission tomography (PET) scanning in non-small cell lung cancer has had this effect. Methods: We performed a retrospective analysis involving 12 395 patients with non-small cell lung cancer in the pre-PET (1994-1998) and PET (1999-2004) periods. Interperiod differences in staging procedures, clinical variables, and patient survival were evaluated. Results: There was a 5.4% decline in the number of patients with stage III disease and an 8.4% increase in the number of patients with stage IV disease in the PET period, corresponding with an increase in PET use from 6.3% to 20.1% (P < .001). The PET period predicted better survival with a hazard ratio (HR) of 0.95 (95% confidence interval [CI], 0.91-0.99) (P = .02). Use of PET was independently associated with better survival in patients with stage III (HR, 0.77; 95% CI, 0.69-0.85) and stage IV (HR, 0.64; 95% CI, 0.58-0.70) disease, but not those with stage I or II disease. Conclusion: These data support the notion that stage migration is responsible at least in part for an apparent improvement in survival for patients with stage III and IV non-small cell lung cancer in the PET scan era.
引用
收藏
页码:1541 / 1549
页数:9
相关论文
共 29 条
[1]  
[Anonymous], CHEST
[2]   Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? [J].
Bunn, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :23S-33S
[3]  
*CAL DEP HLTH SERV, 2006, CAL CANC REP SYST ST, V1
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[6]  
2-B
[7]   THE ROGERS,WILL PHENOMENON - STAGE MIGRATION AND NEW DIAGNOSTIC-TECHNIQUES AS A SOURCE OF MISLEADING STATISTICS FOR SURVIVAL IN CANCER [J].
FEINSTEIN, AR ;
SOSIN, DM ;
WELLS, CK .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25) :1604-1608
[8]  
Fritz A, 2000, International classification of diseases for oncology, V3rd
[9]  
Greene FL., 2002, AJCC CANC STAGING HD, V6th
[10]   Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].
Herbst, RS ;
Giaccone, G ;
Schiller, JH ;
Natale, RB ;
Miller, V .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794